Previous Article | Next Article ![]()
Journal of Virology, June 1999, p. 4962-4971, Vol. 73, No. 6
Department of Biology1
and Department of Chemistry,3 Indiana
University at Bloomington, Bloomington, Indiana, and
Department of Molecular Genetics and Microbiology, University
of Massachusetts Cancer Center, Worchester,
Massachusetts2
Received 25 September 1998/Accepted 26 February 1999
RNA molecules that bind tightly and specifically to a Rex fusion
protein have been isolated from a conformationally constrained pool of
random sequence RNAs. The anti-Rex aptamers effectively mimic several
features of the wild-type Rex-binding element (XBE). The
highest-affinity aptamers effectively compete with the wild-type XBE
for binding to the RNA-binding domain of Rex, an arginine-rich motif
(ARM), but do not bind to the functionally analogous Rev protein or its
ARM. However, characteristic sequence and structural motifs found in
some of the anti-Rex aptamers may provide insights into how the Rex
protein can interact with other viral RNAs, such as the Rev-responsive
element. The anti-Rex aptamers can functionally substitute for the XBE
in vivo, a result which supports a previously proposed model for mRNA
transport in which the viral genome serves as a platform for assembling
a nucleoprotein complex that can co-opt the cellular transport
apparatus. Overall, these studies suggest that anti-Rex aptamers may
serve as RNA decoys of the Rex protein.
Human T-cell leukemia virus type 1 (HTLV-1) is etiologically associated with adult T-cell leukemia, a
malignancy of CD4+ cells (26, 60), and with
tropical spastic paraparesis, a degenerative neuropathy (15,
39). Estimates of the numbers of infected individuals range from
10 to 20 million worldwide (38). HTLV-1 replication is
largely regulated by the virus-encoded proteins Tax and Rex. Tax is a
nuclear trans-activator that forms complexes with cellular
transcription factors and stimulates transcription from promoters
within the viral long terminal repeat (6, 36, 61). Rex
functions posttranscriptionally, enhancing the cytoplasmic appearance
of incompletely spliced mRNAs encoding HTLV-1 structural proteins and
suppressing the appearance of completely spliced mRNAs encoding
regulatory proteins such as Tax and Rex (22, 24, 25, 30). In
effect, Rex modulates the switch between the early phase of the
life cycle, in which viral regulatory proteins are produced, and the
late phase, in which viral particles are assembled (reviewed by Cullen
[11]). Because of its central role in regulating viral
replication and the progression of infection, Rex is an excellent
target for the development of antiviral compounds.
The appearance of singly spliced or unspliced messages in the cytoplasm
is mediated in part by the trans-acting Rex protein (25, 30) and the cis-acting Rex-responsive
element (XRE) located in the 3' untranslated region (2, 24,
44). It is likely that Rex also interacts with a portion of the
5' untranslated region and that RNA transport is dependent on the
formation of a ternary complex between Rex and the two distinct
Rex-binding sites (3, 14). Mutational analysis has indicated
that an arginine-rich motif (ARM) at the amino terminus of Rex
contributes to RNA binding (8, 20, 23). The sequences and
structures that contribute to the function of the 3' XRE (referred to
as simply the XRE) have been studied by a variety of methods, including site-directed mutation, in vitro selection, chemical protection, nuclease protection and modification interference (5, 9, 21, 24,
50). Overall, these experiments have mapped the primary
Rex-binding element (XBE) to stem IID. A minimal version of the
Rex-binding element that can still specifically bind the Rex protein
contains only 24 residues and folds into a stem-bulge structure (see
Fig. 1A) (9).
Since Rex interacts with a defined RNA substrate, it may prove possible
to treat or prevent HTLV-1 infections by using small RNA molecules to
decoy Rex and inhibit its function. For example, the human
immunodeficiency virus type 1 (HIV-1) TAR element and the
HIV-1 Rev-binding element (RBE) are small defined RNA molecules that
interact with the HIV-1 Tat and Rev proteins, respectively. When these
RNA molecules are expressed in tissue culture cells, they decoy Tat and
Rev and inhibit HIV-1 infection (33, 46).
In vitro selection has previously proven to be a valuable tool for
identifying novel inhibitors of protein function (12, 18,
32). In particular, we and others have selected RNA molecules (aptamers) from random sequence pools that bind with high affinity and
specificity to the Rev protein and disrupt interactions between Rev and
the RBE (4, 16, 53). When expressed in cells, the anti-Rev
aptamers can suppress Rev function and inhibit viral replication
(19).
We have now used an in vitro selection approach to identify
high-affinity RNA aptamers that bind to the Rex protein and, more specifically, to the Rex ARM. In addition to potentially serving as
inhibitors of Rex function and viral replication, these anti-Rex aptamers should prove useful in more completely defining how RNA molecules mediate Rex responsiveness. For example, it is currently unclear whether the sequence and architecture of the XRE play a role in
Rex responsiveness beyond merely providing a binding site for
Rex. To address this question, we cloned the anti-Rex aptamers into the
XRE in place of the XBE and assayed the resultant constructs for Rex
responsiveness. Similarly, it is known that the Rex protein binds to a
portion of the Rev-responsive element (RRE) and can functionally
substitute for Rev (8, 43). By comparing the sequences and
structures of the anti-Rex aptamers with the RRE we can begin to
address whether the observed cross-recognition is fortuitous or is the
result of a previously unknown overlap in the binding specificities of
Rex and Rev.
Materials.
Oligonucleotide primers were synthesized on a
model 391 Applied Biosystems DNA synthesizer and purified by denaturing
polyacrylamide gel electrophoresis. All restriction enzymes were from
Promega (Madison, Wis.); Taq polymerase
(AmpliTaq) was from Perkin-Elmer (Norwalk, Conn.). The
GST-Rex fusion protein used in these studies has previously been
described and includes the first 79 amino acids of the Rex protein
followed by a stop codon at position 80 (5).
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Anti-Rex Aptamers as Mimics of the
Rex-Binding Element

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Random sequence RNA pools. An RNA pool (79.9) that contained two random sequence tracts of 6 to 9 residues and that was designed to form a stem-internal loop-stem structure was used as a starting point for in vitro selection experiments (see Fig. 1B). This pool was previously described by Giver et al. (16). In short, a DNA oligonucleotide corresponding in sequence to the RNA pool was chemically synthesized and amplified by PCR. One of the primers used for amplification contained a T7 RNA polymerase promoter sequence. Approximately 0.5 µg of the amplified template was added to an Ampliscribe transcription reaction (Epicentre Technologies, Madison, Wis.). Approximately 30 µg of the initial RNA pool was obtained following purification on a 10% denaturing polyacrylamide gel.
Competitor RNAs. tRNA (Boehringer Mannheim, Indianapolis, Ind.) was used as a nonspecific competitor for RNA binding to Rex. Stem IID of the XRE was used as a specific competitor and was transcribed from XhoI-cut pGEM-XRE. Plasmid pGEM-XRE contains residues 143 through 223 of the XRE (numbering as in Bogerd et al. [9]); some polylinker sequences were also present in the resultant transcript.
In vitro selection of anti-Rex aptamers. Anti-Rex aptamers were isolated from the 79.9 pool by iterative selection for binding followed by amplification of bound species. In each round of selection, tRNA and Rex protein (see Table 1 for amounts) were incubated for 10 min at ambient temperature in 30 µl of 1× binding buffer (50 mM Tris-HCl [pH 8.0], 50 mM KCl). The RNA pool in 20 µl of 1× binding buffer was heated to 90°C for 2 min, was cooled to ambient temperature over 10 min to equilibrate conformers, and in some rounds was passed over HAWP 25 modified cellulose filters (Millipore, New Bedford, Mass.) to remove filter-binding sequences. The solutions containing the Rex protein and the RNA pool were mixed; in some rounds a specific competitor RNA, the XRE, was also thermally equilibrated and added to the mixture (see Table 1). The final reaction mix (60 µl) was incubated at ambient temperature for 60 min. The amounts and final concentrations of tRNA, Rex, pool RNA, and XRE were varied during the course of selection as detailed in Table 1. RNA-protein complexes were separated from free RNA by vacuum filtration (5 mm Hg) over HAWP 25 modified cellulose filters (Millipore). Following application of the RNA-protein mixtures, filters were washed twice with 500 µl of 1× binding buffer. The final two rounds of selection included a dilution step following the binding reaction; the dilution step would have favored the retention of RNA-protein complexes with low off-rates. RNAs that were coretained with Rex were eluted from the filters with 400 µl of 2× PK buffer (0.2 M Tris-Cl [pH 7.6], 2.5 mM EDTA, 0.3 M NaCl, 2% SDS) for 30 min at 75°C. The eluate was extracted with phenol-chloroform and precipitated with ethanol, and the pellet was resuspended in 25 µl of water.
RNA for subsequent rounds of selection was synthesized by a combination of reverse transcription, PCR amplification, and in vitro transcription. A portion of the extracted RNA (10 µl) was reverse transcribed in a reaction mix (20 µl) that contained 40 mM KCl, 50 mM Tris-Cl (pH 8.0), 6 mM MgCl2, 0.4 mM deoxynucleoside triphosphates (dNTPs), 5 mM dithiothreitol (DTT), 2.5 µM primer 20.86 (5' CGTGGATCCGATAGATAGGC 3'), and 5 U of avian myeloblastosis virus reverse transcriptase (RT) (Seikagaku, St. Petersburg, Fla.). dNTPs, DTT, and RT were added following an initial annealing step (3 min at 75°C; 5 min at ambient temperature). The reaction mix was then incubated at 42°C for 45 min. For PCR amplification, 15 µl of this reaction mix was diluted in 85 µl of PCR mix (10 mM Tris-Cl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2, 5% acetamide, 0.05% NP-40, 200 µM dNTPs, 2.5 U of Taq polymerase, 0.5 µM primer 37.17 [5' GGTAATACGACTCACTATAGGGAACTCGATGAAGCGA 3'], and 0.5 µM primer 20.86). The reaction mix was thermally cycled (94°C, 45 s; 45°C, 1 min; 72°C, 2 min) until a product band of the correct size was observed on an agarose gel. Control reactions without template were carried out in parallel; no amplification products were detected in control reactions. PCR template (5 µl [50% of a precipitated PCR mix resuspended in Tris-EDTA, pH 8.0]) was added to an Ampliscribe transcription reaction, and RNA transcripts were isolated from a denaturing polyacrylamide gel. PCR products (1 µg) from the fourth and eighth rounds of selection were ligated into a TA cloning vector (Invitrogen) according to the protocol provided. Sequence data were generated from recombinant clones by standard dideoxy sequencing protocols.Binding assays.
Pool RNAs were assayed for the ability to be
coretained with the Rex protein on modified cellulose filters.
Unselected and selected RNA pools were internally labeled by including
1 µl of [
-32P]UTP (3,000 Ci/mmol) (Dupont NEN) in an
Ampliscribe transcription reaction. RNA transcripts were gel purified
and resuspended in distilled water. As in the selection procedure, tRNA
and Rex fusion protein were mixed and incubated at ambient temperature
for 10 min. Pool RNA was thermally equilibrated at 75°C for 2 min
followed by cooling to ambient temperature over 10 min. The solutions
containing the Rex protein and the pool RNA were mixed in 1× binding
buffer (0.96 µM final concentration of pool RNA, 9.6 µM tRNA, and
20 nM Rex fusion protein in a 40-µl final volume). The binding
reaction was incubated at ambient temperature for 1 h, the mixture
was filtered, and the filters were washed twice with 500 µl of 1× binding buffer. The amount of radioactive RNA that was coretained with
protein was quantitated with a PhosphorImager (Molecular Dynamics,
Sunnyvale, Calif.). The amount of RNA that bound to the filter alone in
the absence of protein (generally less than 1% of applied counts) was
independently determined and subtracted from the protein-dependent signal.
Competition assays.
In competition assays, pool RNAs (20 µl) were thermally equilibrated (90°C for 2 min, followed by
cooling to ambient temperature over 10 min) and combined with stem IID
of the XRE (20 µl), an excess of tRNA (20 µl), and 15 nM Rex
protein in 1× binding buffer (0.59 µM pool RNAs, 0.64 µM stem IID,
and 6.6 µM tRNA in a 60-µl final volume). The reaction was
incubated, filtered, and eluted as in the selection experiments. After
precipitation, samples were resuspended in 4 µl of stop dye (7 M
urea, 1× TBE, 0.1% bromophenol blue) and electrophoretically
separated on a denaturing 10% polyacrylamide gel. The amount of
radioactivity in each band was determined with a PhosphorImager
(Molecular Dynamics). Binding ratios were calculated by the formula
{[(counts filtered)pool
background]/[(counts unfiltered)pool
background]}/{[(counts
filtered)stem IID
background]/[(counts unfiltered)stem IID
background]}. The binding ratio
represent an estimate of the aggregate affinity of pool RNAs for Rex
relative to wild-type stem IID.
RNA titration experiments. To estimate the dissociation constants of aptamer-Rex complexes, the amount of RNA retained on filters was determined as a function of RNA concentration. Transfer RNA (1 µg) was combined with 18 nM Rex and varying concentrations of thermally equilibrated (75°C for 3 min; ambient temperature for 10 min) aptamers in 1× binding buffer (50-µl final volume). The reaction mixture was incubated for 1 h at ambient temperature and filtered, and the amount of RNA retained was quantitated with a PhosphorImager. To determine the specific activity of an RNA sample, 5 µl of a 300 nM solution was spotted onto a modified cellulose filter and separately quantitated on a PhosphorImager. The number of moles of RNA bound by protein was estimated based on the number of counts retained on modified cellulose filters and the specific activity of the RNA. Moles of RNA retained was plotted against the concentration of RNA in each reaction mix. A simple bimolecular interaction between Rex and anti-Rex aptamers was consistent with the binding data, and dissociation constants were estimated by a least squares fit of the data (Kaleidograph; Abelbeck Software, Reading, Pa.).
Mobility shift assays. Interactions between aptamers and ARM proteins were monitored with a mobility shift assay. Following thermal equilibration in 1× binding buffer (75°C for 2 min; ambient temperature for 10 min), 10 ng of 32P-end-labeled aptamer RNA was mixed with 2 µg of tRNA and varying amounts of either HTLV-1 Rex fusion protein or HIV-1 Rev protein in 10 µl of 1× binding buffer. This reaction mixture was allowed to equilibrate for 1.5 h at ambient temperature. The reaction was gently mixed with 2 µl of 6× nondenaturing dye (0.25% bromophenol blue, 40% glycerin in double-distilled water) immediately prior to gel electrophoresis. RNA-protein complexes were resolved from free RNA on an 8% native polyacrylamide gel (19:1 bis-acrylamide, 1× TBE; 5 W). Electrophoresis was carried out at ambient temperature until the bromophenol blue had run 12 cm into the gel. Bands were visualized with a PhosphorImager.
Mobility shift experiments were also carried out with a minimal version of the 8-5 aptamer (min-apt) and peptides corresponding to the Rex and Rev ARMs. The minimal aptamer was transcribed from a hemiduplex generated from the following DNA oligonucleotides: T7 primer, 5' GAAATTAATACGACTCACTATAG 3'; template, 5' GGGCGTACCGTCGTACTTGCGTACCGGCGCCCTATAGTGAGTCGTATTAATT 3'. The sequence of the template spans the conserved core of aptamer 8-5 and is similar to the sequence of clone 39b. The following peptides were used for mobility shift experiments and represent the ARMs of Rex and Rev, respectively: Rex ARM, MPKTRRRPRRSQRKRP-am (57); Rev ARM, suc-TRQARRNRRRRWRERQRAAAAR-am (48), where "suc" indicates succinylation of the amino terminus and "am" indicates amidation of the carboxy terminus. These peptides were synthesized by Amgen (Boulder, Colo.), and their purity was verified by HPLC and mass spectrometry. The end-labeled minimal aptamer and various amounts of Rex ARM peptide or Rev ARM peptide were incubated together in 10 µl of modified binding buffer (50 mM Tris-HCl, 50 mM KCl, 1 mM MgCl2, 5% glycerol, 5 ng of RNA) at 4°C for 1 h. Aptamer-peptide complexes were separated from free aptamer on a 10% native polyacrylamide gel (59:1 bis-acrylamide, 0.5× TBE; 350 V) at 4°C.Construction of XRE chimeras. Plasmids in which aptamer sequences were inserted into the XRE in place of the XBE were constructed. Plasmid pGEM REM 8 was used as the backbone for the construction of aptamer-XRE chimeras. This plasmid is an XRE deletion mutant and fails to support Rex responsiveness in vivo (2). The plasmid contains a unique BglII site in place of stem IID of the XRE, as well as an XbaI site at each end of the XRE (24). Aptamer inserts 8-5 and 9A were prepared by PCR amplification of aptamer templates cloned into pCRII. The primers used for amplification introduce BglII sites at the 5' and 3' ends of the insert and have the following sequences: forward 8-5 primer, 5' GGGAGATCTCGAGATAGGCCGGCGC 3'; reverse 8-5 primer, 5' GGGAGATCTGTAGGCGACGGTA 3'; forward 9A primer, 5' GGGAGATCTCGAGCCTGTCCGGTGA 3'; reverse 9A primer, 5' GGGAGATCTGTCGACGGGTACG 3'. Underlined sequences correspond to residues originally found in the aptamer.
The pGEM REM 8 backbone was linearized with BglII and ligated to the 8-5 or 9A aptamer DNAs that were also cleaved with BglII. Recombinant clones were isolated, and the XRE chimeras were excised from the pGEM background by restriction with XbaI. The XbaI restriction fragments were filled in by T4 DNA polymerase to form blunt ends, and the blunt restriction fragments were ligated into a unique, blunted ClaI site in plasmid pCMV138 (previously described by Luo et al. [35]). Plasmid pCMV138 is identical to pDM138 (29) except that it contains the cytomegalovirus (CMV) promoter region in place of the simian virus 40 promoter. The sequences of the inserts in the final recombinant clones were verified by standard dideoxy sequencing methods.Transfection experiments.
CV-1 African green monkey kidney
cells were grown in 1× DMEM containing 11% heat-inactivated fetal
calf serum, 35 mM Na2CO3, and 25 mM HEPES (pH
7.1). Twenty-four hours prior to transfection, cells were seeded at
75% confluency in 60-mm culture dishes. Transient transfection assays
for Rex function were performed by a calcium phosphate-mediated DNA
transfection protocol previously described by Lin and Green
(34) and included the following modifications. Each
transfection mixture contained 1 µg of a given CMV promoter-driven wild-type XRE or XRE chimera reporter plasmid, 0.75 µg of the pcREX
expression plasmid, and 2 µg of a
-galactosidase expression plasmid (pRSV-
-gal; Promega) as an internal control for both transfection efficiency and gene expression. The total DNA
concentration was adjusted to 10 µg with a plasmid containing the CMV
promoter (but no downstream insert) or with pUC119 DNA. Transfected
cells were harvested 48 h posttransfection. CAT levels were
determined with a CAT assay previously described by Hope et al.
(28);
-galactosidase levels were determined using a
-galactosidase assay previously described by Lin and Green
(34).
| |
RESULTS |
|---|
|
|
|---|
In vitro selection of anti-Rex aptamers. The minimal Rex-binding element (XBE) has previously been shown by deletion mapping (2), mutational analysis (21), modification interference studies (9), and in vitro selection experiments (5) to form a relatively short stem-bulge RNA secondary structure in which the identities of as few as 10 residues may be critical for Rex-binding function (Fig. 1A). The compactness of the XBE is similar to the compactness observed for other RNA molecules that bind ARMs (16, 53, 55, 58, 59).
|
|
Novel, high-affinity RNA ligands for Rex. Individuals from the fourth and eighth rounds of selection were cloned and sequenced, and sequences were aligned. The round 4 aptamers could be divided into three families based on their primary sequences (Fig. 2). The relative binding affinities of the round 4 aptamers were determined in competition with stem IID (Fig. 2) and ranged from 0.6-fold of wild-type levels to roughly 9-fold higher than wild-type levels. The highest-affinity aptamers could be found in class I, while aptamers of intermediate affinity were dispersed between all three families.
|
|
Characterization of the 8-5 aptamer. Aptamer 8-5 was assayed for the ability to bind to Rex. A binding curve was generated by incubating increasing amounts of RNA with a constant amount of Rex protein and capturing aptamer-Rex complexes by filtration. The Kapp of the aptamer-Rex complex was estimated to be 30 nM (Fig. 4A). In a complementary experiment, increasing amounts of protein were incubated with a constant amount of RNA and the formation of the aptamer-Rex complex was monitored by a gel mobility shift. The formation of the aptamer-Rex complex was again found to be concentration dependent, and the Kapp was similar (25 nM [Fig. 4B]).
|
|
Aptamers selected in vitro are functional in vivo. The high affinity, specificity, and stability of the selected aptamer-Rex complex and the fact that the aptamer effectively competes with the XBE for binding to Rex in vitro suggested that the aptamer might effectively mimic the function of the XBE in vivo. A reporter system that had previously been used to assay mRNA transport was adapted to assay anti-Rex aptamer function (Fig. 6A). In plasmid pCMV138, a reporter gene, CAT, is present in an HIV-1 intron and sequences responsible for Rev-dependent cytoplasmic transport (the Rev-responsive element) have been deleted from the intron. Thus, when pCMV138 is transfected into cells, mRNAs containing the HIV-1 intron are transcribed, the intron is spliced out, and the gene encoding CAT is degraded. However, when the XRE is introduced into the HIV-1 intron in place of the RRE and the plasmid is cotransfected with a Rex expression plasmid, unspliced mRNAs are transported to the cytoplasm and the gene encoding CAT is translated. In effect, expression of the CAT activity in pCMV138 is dependent on the dual presence of RNA elements and protein factors that can facilitate cytoplasmic transport (28, 37). This system therefore affords an opportunity to assay anti-Rex aptamers for the ability to bind Rex and support mRNA transport in vivo.
|
8)] was
not Rex responsive (less than 5% of wild-type activity). In contrast,
aptamer 8-5 [Rex 8-5 (
8)] appeared to support Rex-responsive mRNA
transport, although the hybrid XRE was less Rex responsive than the
wild-type XRE (46% of wild-type activity [Fig. 6B]).
| |
DISCUSSION |
|---|
|
|
|---|
High-affinity aptamers that bind to a Rex fusion protein of HTLV-1 have been isolated from a short, conformationally constrained pool of RNA. While a longer pool could potentially have been used to derive aptamers, in order to make sure that anti-Rex aptamers were also Rex antagonists we wished to mimic as closely as possible the known sequence and structural requirements of the Rex-binding element. Moreover, we have previously observed that aptamers selected from both shorter (<30) and longer (>30) random sequence pools contained the same short consensus sequence and structural motifs (a phenomenon termed the "tyranny of short motifs"). Thus, it seemed likely that we might more fully cover sequence space with a shorter pool yet still extract the same high-affinity elements as with a longer random sequence pool. Finally, since the 79.9 pool had previously been used for selection of aptamers that could bind to HIV-1 Rev (16), it proved possible to directly compare the sequences, structures, and specificities of anti-Rex and anti-Rev aptamers.
The stringency of selection was graded in order to efficiently drive the selection process. Protein concentration, competitor concentration, and equilibrium dynamics were systematically varied, and low-affinity or non-specifically binding RNA molecules were eliminated from the population within a few rounds. The selected pool showed a marked improvement over the unselected pool and bound Rex severalfold better than isolated stem IID of the XRE, which contains the XBE. The aggregate improvement in the binding ability of the pool was mirrored by improvements in the affinities of individual aptamers between rounds. Between rounds 4 and 8, low-affinity class III molecules had been eliminated from the population, only a minor set of class II sequences remained, and the highest-affinity binding species in class I predominated. When assayed in direct competition with stem IID, individual aptamers from round 8 bound either as well as or up to ninefold better than the XBE.
Although sequences and structures similar to the wild-type XBE would have been contained in the original random sequence pool, the sequences of the best anti-Rex aptamers (class I) do not closely resemble the sequence of the XBE. Moreover, although both class I aptamers and the XBE contain dinucleotide bulges separated by a central, base-paired triplet, the bulged nucleotides are on the same strand in class I aptamers but on opposing strands in the XBE. The isolation of such non-wild-type RNA-binding species from completely randomized pools has previously been observed. For example, RNA hairpins selected to bind phage T4 DNA polymerase bore little resemblance to the wild-type sequence (51), while RNA aptamers that bound HIV-1 RT were predicted to form a unique pseudoknot structure that differed from a tRNA cloverleaf (52). Sequence differences between natural and in vitro-selected RNA ligands may be the result of biological restrictions on natural selection, such as codon usage or RNA folding in the context of a viral genome, that have no counterpart in in vitro selection experiments.
Both class I aptamers and the XBE interact with the same site on the Rex protein, the ARM that lies between residues 1 and 16. Since the constant sequence helices in the original pool have been retained in the predicted structures of the anti-Rex aptamers, it is likely that selected residues in the formerly random region are not involved in structure presentation but instead directly participate in contacts with the Rex ARM. In support of this hypothesis, anti-Rev aptamers have previously been selected from the same random sequence pool and structural studies have revealed that many of the selected residues directly contact the Rev protein (16, 58).
Our results may also help to resolve conflicting reports in the
literature over whether and how the wild-type Rex ARM interacts with
the XBE or XRE. Hope and coworkers have shown when the Rev and Rex
proteins are fused, the Rex ARM is dispensible for Rex-dependent mRNA
transport (29). These results are supported in part by the
work of Bohnlein, Hauber, and their coworkers, who have demonstrated that Rex deletion variants that lack an ARM can nonetheless mediate Rex-dependent mRNA transport, albeit at reduced levels (27). In contrast, Grassmann and coworkers (20) have shown that
Rex deletion variants that lack an ARM do not bind well to the XRE in
vitro. Nonconservative substitutions in the Rex ARM (Arg5-Arg6-Arg7 to
Asp-Leu) disrupt the function of Rex (42) and the ability of
Rex to bind to the XRE (8). Similarly, Hammes and Greene (23) have demonstrated that conservative lysine-for-arginine substitutions within the ARM can abrogate Rex-dependent mRNA transport. Since the anti-Rex aptamers bind the Rex ARM and also directly compete
with the XBE for binding to Rex, our results strongly imply that Rex
must also bind to the XBE via its ARM. In support of this conclusion,
when the Rex ARM is fused to a heterologous proteins
(
-galactosidase), weak binding to the XRE can be demonstrated (20). However, as a caveat to this discussion it should be
noted that additional XBE binding sites within Rex may fall outside the
ARM, as suggested by Bohnlein et al. (10) and Weichselbraun and coworkers (56).
Precisely because class I aptamers do not resemble the XBE yet bind to the same site on Rex, they should prove to be useful reagents for probing the role of RNA sequence and structure in Rex-mediated RNA transport. The highest-affinity aptamer, 8-5, was cloned into the XRE in place of the XBE and was found to efficiently support Rex-responsive mRNA transport, though not as well as the wild-type XRE. The diminished activity of the chimeric XRE may be a result of not knowing precisely how to substitute the aptamer for the XBE or how to position the aptamer relative to other Rex-binding sites on the XRE, such as an adjacent Rex-binding site mapped by Askjaer and Kjems (3). It is also possible that the binding affinities of aptamers in the in vivo cellular milieu are different than those calculated based on in vitro binding reactions. However, while the requirements for transport function or protein binding may be more stringent in vivo than in vitro, it is nonetheless impressive that an unnatural RNA element selected solely on the basis of its ability to bind Rex can support Rex-dependent RNA transport. Moreover, the fact that a high-affinity anti-Rex aptamer supports mRNA transport better than a low-affinity anti-Rex aptamer supports the contention that the aptamers are serving as functional substitutes for the XBE.
Overall, these findings support and complement other mechanistic studies of viral mRNA transport. Current models for the mechanism of Rex responsiveness suggest that the cellular mRNA transport apparatus interacts with the Rex protein through an effector domain (7, 13, 45). The effector domains of Rex and Rev are similar, and when these domains are swapped for one another the chimeric proteins can still facilitate cytoplasmic mRNA transport (56). These ARM proteins therefore appear to function as simple connectors that transitively bind viral RNA to the cellular machinery. We now show that the XRE may contribute little to this connection beyond the ability to act as a handle for Rex binding. This interpretation accords with a previous study in which anti-Rev aptamers substituted for the RBE within the RRE were found to support Rev responsiveness (47).
Taken together, our results suggest that it may be possible to use class I aptamers as intracellular decoys for Rex and, thus, as inhibitors of HTLV-1 replication. First, since aptamer 8-5 can functionally substitute for the XBE, it likely interacts with the Rex protein in vivo. Second, since aptamer 8-5 binds specifically to the Rex protein and Rex ARM, eschewing interactions with the similarly charged, functionally analogous Rev protein and Rev ARM even at high peptide concentrations, it should not bind nonspecifically to other cellular or viral proteins. Third, the essential sequences and structures of aptamer 8-5 can be reduced to a synthetically accessible 22-nucleotide RNA by the incorporation of synthetic linker elements; the minimal construct shows no loss of binding activity (39a). Finally, a similar strategy based on intracellular expression of anti-Rev aptamers has proven successful at inhibiting HIV-1 replication (19, 33).
Other anti-Rex aptamers showed a greater resemblance to the wild-type XBE and to other RNA molecules that bind ARMs. Class II aptamers contained a conserved sequence motif, 5' UUGAG ... CUC 3', that was predicted to form a short stem adjacent to a bulge loop (Fig. 7). A similar sequence is also found in the wild-type XBE and is also predicted to form a stem-bulge structure. In vitro selection experiments with partially randomized populations based on the wild-type XBE have previously shown that the 5' UUGAG ... CUC 3' stem-bulge is important for Rex binding (5). Moreover, an XBE "half-site" that contains the stem-bulge and that resembles class II aptamers can bind Rex (5).
|
The stem-bulge sequence and structural motif seen in class II aptamers and in the XBE is similar to a stem-bulge that has been predicted to form in HIV-1 TAR (Fig. 3A, Fig. 7). Structural studies of TAR have revealed that the stem-bulge forms a compact pocket that can interact with one of the arginines in the ARM of HIV-1 Tat (41). In a Tat-TAR complex, the guanidino group of arginine is thought to form a pseudo-Hoogsteen pair with the G:C base pair adjacent to the bulge, while the bulged U residue forms a base triple with A:U that pulls the negatively charged phosphate backbone into apposition with the positively charged arginine.
A number of groups have previously found that Rex can recognize the RRE and functionally substitute for HIV-1 Rev (2, 8, 10, 24, 43, 54, 56). The primary Rex-binding site on the RRE appears to be different from the primary Rev-binding site: Rev binds first to stem II of the RRE, while Rex binds to a region that includes stems IV and V (2, 54). Since the anti-Rex aptamers we have identified serve as examples of individual Rex-binding sites, we compared the sequences and structures of the anti-Rex aptamers with the sequence and structure of the RRE. Surprisingly, a paired 5' GAG ... CUC 3' triplet is found adjacent to a U-rich single-stranded region in stem IV/V of the RRE. This putative arginine-binding pocket differs from those observed previously in that a homopurine base pair may separate paired and single-stranded regions. However, arginine-binding pockets based on the 5' GAG ... CUC 3' motif have previously been shown to be structurally diverse: mutational analysis of the TAR element indicates that two- to four-base bulges are functional and bovine immunodeficiency virus TAR bisects the bulge-loop with a base pair (Fig. 7). To the extent that the putative arginine-binding pocket in RRE stem IV/V and the arginine-binding pockets predicted to form in class II anti-Rex aptamers and in the XBE are functionally equivalent, our selection results may provide a basis for understanding how Rex recognizes the RRE.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Chemistry, ICMB A4800, 26th and Speedway, University of Texas at Austin, Austin, TX 78712. Phone: (512) 232-3424. Fax: (512) 471-7014. E-mail: andy.ellington{at}mail.utexas.edu.
Present address: Whitehead Institute for Biomedical Research,
Cambridge, MA 02142.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aboul-ela, F., J. Karn, and G. Varani. 1995. The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J. Mol. Biol. 253:313-332[Medline]. |
| 2. |
Ahmed, Y. F.,
S. M. Hanly,
M. H. Malim,
B. R. Cullen, and W. C. Greene.
1990.
Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action.
Genes Dev.
4:1014-1022 |
| 3. |
Askjaer, P., and J. Kjems.
1998.
Mapping multiple RNA binding sites of human T-cell lymphotropic virus type I Rex protein within 5'- and 3'-Rex response elements.
J. Biol. Chem.
273:11463-11471 |
| 4. | Bartel, D. P., M. L. Zapp, M. R. Green, and J. W. Szostak. 1991. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell 67:529-536[Medline]. |
| 5. | Baskerville, S., M. Zapp, and A. D. Ellington. 1995. High-resolution mapping of the human T-cell leukemia virus type 1 Rex-binding element by in vitro selection. J. Virol. 69:7559-7569[Abstract]. |
| 6. | Beraud, C., G. Lombard-Platet, Y. Michal, and P. Jalinot. 1991. Binding of the HTLV-1 Tax 1 transactivator to the inducible 21 bp enhancer is mediated by the cellular factor HEB1. EMBO J. 10:3795-3803[Medline]. |
| 7. | Bogerd, H. P., R. A. Fridell, S. Madore, and B. R. Cullen. 1995. Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 82:485-494[Medline]. |
| 8. |
Bogerd, H. P.,
G. L. Huckaby,
Y. F. Ahmed,
S. M. Hanly, and W. C. Greene.
1991.
The type I human T-cell leukemia virus (HTLV-I) Rex trans-activator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements.
Proc. Natl. Acad. Sci. USA
88:5704-5708 |
| 9. |
Bogerd, H. P.,
L. S. Tiley, and B. R. Cullen.
1992.
Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex response element.
J. Virol.
66:7572-7575 |
| 10. |
Bohnlein, E.,
J. Berger, and J. Hauber.
1991.
Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex.
J. Virol.
65:7051-7055 |
| 11. |
Cullen, B. R.
1992.
Mechanism of action of regulatory proteins encoded by complex retroviruses.
Microbiol. Rev.
56:375-394 |
| 12. | Ellington, A. D., and R. Conrad. 1995. Aptamers as potential nucleic acid pharmaceuticals. Biotechnol. Annu. Rev. 1:185-214[Medline]. |
| 13. | Fritz, C. C., M. L. Zapp, and M. R. Green. 1995. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 376:530-533[Medline]. |
| 14. | Fu, L., and K. N. White. 1996. Enhancement of nucleocytoplasmic export of HTLV-I Rex mRNA through cis and trans interactions of the mRNA with the complex of Rex protein and Rex-responsive element. FEBS Lett. 396:47-52[Medline]. |
| 15. | Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender, and G. de The. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii:407-410. |
| 16. |
Giver, L.,
D. Bartel,
M. Zapp,
A. Pawul,
M. Green, and A. D. Ellington.
1993.
Selective optimization of the Rev-binding element of HIV-1.
Nucleic Acids res.
21:5509-5516 |
| 17. | Giver, L., D. P. Bartel, M. I. Zapp, M. R. Green, and A. D. Ellington. 1993. Selection and design of high-affinity RNA ligands for HIV-1 Rev. Gene 137:19-24[Medline]. |
| 18. | Gold, L. 1995. Conformational properties of oligonucleotides. Nucleic Acids Symp. Ser. 33:20-22. |
| 19. | Good, P. D., A. J. Krikos, S. X. Li, E. Bertrand, N. S. Lee, L. Giver, A. Ellington, J. A. Zaia, J. J. Rossi, and D. R. Engelke. 1997. Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4:45-54[Medline]. |
| 20. |
Grassmann, R.,
S. Berchtold,
C. Aepinus,
C. Ballaun,
E. Boehnlein, and B. Fleckenstein.
1991.
In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts.
J. Virol.
65:3721-3727 |
| 21. | Grone, M., E. Hoffmann, S. Berchtold, B. R. Cullen, and R. Grassmann. 1994. A single stem-loop structure within the HTLV-1 Rex response element is sufficient to mediate Rex activity in vivo. Virology 204:144-152[Medline]. |
| 22. | Grone, M., C. Koch, and R. Grassmann. 1996. The HTLV-1 Rex protein induces nuclear accumulation of unspliced viral RNA by avoiding intron excision and degradation. Virology 218:316-325[Medline]. |
| 23. | Hammes, S. R., and W. C. Greene. 1993. Multiple arginine residues within the basic domain of HTLV-I Rex are required for specific RNA binding and function. Virology 193:41-49[Medline]. |
| 24. |
Hanly, S. M.,
L. T. Rimsky,
M. H. Malim,
J. H. Kim,
J. Hauber,
M. Duc Dodon,
S. Y. Le,
J. V. Maizel,
B. R. Cullen, and W. C. Greene.
1989.
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.
Genes Dev.
3:1534-1544 |
| 25. | Hidaka, M., J. Inoue, M. Yoshida, and M. Seiki. 1988. Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins. EMBO J. 7:519-523[Medline]. |
| 26. |
Hinuma, Y.,
K. Nagata,
M. Hanaoka,
M. Nakai,
T. Matsumoto,
K. I. Kinoshita,
S. Shirakawa, and I. Miyoshi.
1981.
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.
Proc. Natl. Acad. Sci. USA
78:6476-6480 |
| 27. |
Hofer, L.,
I. Weichselbraun,
S. Quick,
G. K. Farrington,
E. Bohnlein, and J. Hauber.
1991.
Mutational analysis of the human T-cell leukemia virus type I trans-acting rex gene product.
J. Virol.
65:3379-3383 |
| 28. |
Hope, T. J.,
B. L. Bond,
D. McDonald,
N. P. Klein, and T. G. Parslow.
1991.
Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif.
J. Virol.
65:6001-6007 |
| 29. |
Hope, T. J.,
D. McDonald,
X. J. Huang,
J. Low, and T. G. Parslow.
1990.
Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus.
J. Virol.
64:5360-5366 |
| 30. |
Inoue, J.,
M. Yoshida, and M. Seiki.
1987.
Transcriptional (p40x) and post-transcriptional (p27x-III) regulators are required for the expression and replication of human T-cell leukemia virus type I genes.
Proc. Natl. Acad. Sci. USA
84:3653-3657 |
| 31. | Jensen, K. B., L. Green, S. MacDougal-Waugh, and C. Tuerk. 1994. Characterization of an in vitro-selected RNA ligand to the HIV-1 Rev protein. J. Mol. Biol. 235:237-247[Medline]. |
| 32. | Klug, S. J., and M. Famulok. 1994. All you wanted to know about SELEX. Mol. Biol. Rep. 20:97-107[Medline]. |
| 33. |
Lee, S. W.,
H. F. Gallardo,
E. Gilboa, and C. Smith.
1994.
Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
J. Virol.
68:8254-8264 |
| 34. | Lin, Y. S., and M. R. Green. 1989. Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements. Nature 340:656-659[Medline]. |
| 35. |
Luo, Y.,
H. Yu, and B. M. Peterlin.
1994.
Cellular protein modulates effects of human immunodeficiency virus type 1 Rev.
J. Virol.
68:3850-3856 |
| 36. |
Marriott, S. J.,
P. F. Lindholm,
K. M. Brown,
S. D. Gitlin,
J. F. Duvall,
M. F. Radonovich, and J. N. Brady.
1990.
A 36-kilodalton cellular transcription factor mediates an indirect interaction of human T-cell leukemia/lymphoma virus type I TAX1 with a responsive element in the viral long terminal repeat.
Mol. Cell. Biol.
10:4192-4201 |
| 37. |
McDonald, D.,
T. J. Hope, and T. G. Parslow.
1992.
Postranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.
J. Virol.
66:7232-7238 |
| 38. | Murphy, E. L., B. Hanchard, J. P. Figueroa, W. N. Gibbs, W. S. Lofters, M. Campbell, J. J. Goedert, and W. A. Blattner. 1989. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int. J. Cancer 43:250-253[Medline]. |
| 39. | Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, A. Igata, M. Matsumoto, and M. Tara. 1986. HTLV-I associated myelopathy, a new clinical entity [letter]. Lancet i:1031-1032. |
| 39a. | Osborne, S. E. Unpublished results. |
| 40. |
Puglisi, J. D.,
L. Chen,
S. Blanchard, and A. D. Frankel.
1995.
Solution structure of a bovine immunodeficiency virus Tat-TAR peptide-RNA complex.
Science
270:1200-1203 |
| 41. |
Puglisi, J. D.,
R. Tan,
B. J. Calnan,
A. D. Frankel, and J. R. Williamson.
1992.
Conformation of the TAR RNA-arginine complex by NMR spectroscopy.
Science
257:76-80 |
| 42. | Rimsky, L., M. D. Dodon, E. P. Dixon, and W. C. Greene. 1989. Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. Nature 341:453-456[Medline]. |
| 43. | Rimsky, L., J. Hauber, M. Dukovich, M. H. Malim, A. Langlois, B. R. Cullen, and W. C. Greene. 1988. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature 335:738-740[Medline]. |
| 44. |
Seiki, M.,
J. Inoue,
M. Hidaka, and M. Yoshida.
1988.
Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I.
Proc. Natl. Acad. Sci. USA
85:7124-7128 |
| 45. | Stutz, F., M. Neville, and M. Rosbash. 1995. Identification of a novel nuclear pore-associated protein as a functional target of the HIV-1 Rev protein in yeast. Cell 82:495-506[Medline]. |
| 46. | Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608[Medline]. |
| 47. | Symensma, T. L., L. Giver, M. Zapp, G. B. Takle, and A. D. Ellington. 1996. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol. 70:179-187[Abstract]. |
| 48. | Tan, R., L. Chen, J. A. Buettner, D. Hudson, and A. D. Frankel. 1993. RNA recognition by an isolated alpha helix. Cell 73:1031-1040[Medline]. |
| 49. | Tao, J., and A. D. Frankel. 1996. Arginine-binding RNAs resembling TAR identified by in vitro selection. Biochemistry 35:2229-2238[Medline]. |
| 50. |
Toyoshima, H.,
M. Itoh,
J.-I. Inoue,
M. Seiki,
F. Takaku, and M. Yoshida.
1990.
Secondary structure of the human T-cell leukemia virus type 1 rex-responsive element is essential for rex regulation of RNA processing and transport of unspliced RNAs.
J. Virol.
64:2825-2832 |
| 51. |
Tuerk, C., and L. Gold.
1990.
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
Science
249:505-510 |
| 52. |
Tuerk, C.,
S. MacDougal, and L. Gold.
1992.
RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
Proc. Natl. Acad. Sci. USA
89:6988-6992 |
| 53. | Tuerk, C., and S. MacDougal-Waugh. 1993. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene 137:33-39[Medline]. |
| 54. |
Unge, T.,
L. Solomin,
M. Mellini,
D. Derse,
B. K. Felber, and G. N. Pavlakis.
1991.
The Rex regulatory protein of human T-cell lymphotropic virus type I binds specifically to its target site within the viral RNA.
Proc. Natl. Acad. Sci. USA
88:7145-7149 |
| 55. | Weeks, K. M., and D. M. Crothers. 1991. RNA recognition by Tat-derived peptides: interaction in the major groove? Cell 66:577-588[Medline]. (Erratum, 70:1069, 1992.) |
| 56. |
Weichselbraun, I.,
G. K. Farrington,
J. R. Rusche,
E. Bohnlein, and J. Hauber.
1992.
Definition of the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex protein activation domain by functional exchange.
J. Virol.
66:2583-2587 |
| 57. |
Xu, W., and A. D. Ellington.
1996.
Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope.
Proc. Natl. Acad. Sci. USA
93:7475-7480 |
| 58. | Ye, X., A. Gorin, A. D. Ellington, and D. J. Patel. 1996. Deep penetration of an alpha-helix into a widened RNA major groove in the HIV-1 rev peptide-RNA aptamer complex. Nat. Struct. Biol. 3:1026-1033[Medline]. |
| 59. | Ye, X., R. A. Kumar, and D. J. Patel. 1995. Molecular recognition in the bovine immunodeficiency virus Tat peptide-TAR RNA complex. Chem. Biol. 2:827-840[Medline]. |
| 60. |
Yoshida, M.,
I. Miyoshi, and Y. Hinuma.
1982.
Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.
Proc. Natl. Acad. Sci. USA
79:2031-2035 |
| 61. |
Zhao, L. J., and C. Z. Giam.
1991.
Interaction of the human T-cell lymphotrophic virus type I (HTLV-I) transcriptional activator Tax with cellular factors that bind specifically to the 21-base-pair repeats in the HTLV-I enhancer.
Proc. Natl. Acad. Sci. USA
88:11445-11449 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»